All News

2061 articles, sorted by publication time.

Cancer and Immunotherapy · us

A New Option to Prevent Colon Cancer Recurrence After Surgery: FDA Approves Tecentriq Plus Chemotherapy

For stage III DNA mismatch repair-deficient colon cancer, adding immunotherapy to postoperative chemotherapy improved the three-year disease-free survival rate by about 10 percentage points. The new approval brings treatment into an earlier setting, but also comes with more severe adverse events. Whether it extends overall survival remains to be determined through follow-up.

Cell Therapy and the Biotech Industry · us

Despite agreement on Phase 3 trial design, Caribou plans to halt two allogeneic CAR-T programs amid financing pressure

Moving from early efficacy signals to large-scale confirmatory trials requires cell therapies to clear a funding hurdle. Caribou plans to end development of vispa-cel and CB-011, substantially reduce its workforce, and seek a merger or asset transaction; patients already treated remain in long-term follow-up studies.

Clinical Research · us

SurVaxM Brain Cancer Vaccine Misses Overall Survival Endpoint, Shows Efficacy Signal in Patients Aged 65 and Younger

A randomized controlled trial has brought both the promise of a glioblastoma vaccine and the limits of the evidence into focus: the overall survival difference was not statistically significant, while a prespecified younger population had better outcomes. Whether this signal can support further development still awaits a complete analysis and regulatory discussions.